GLAXOGlaxosmithkline Pharmaceuticals Ltd.
Glaxosmithkline Pharmaceuticals Q2 FY27 Results: Consolidated Net Profit ₹336 Crore on Total Income of ₹1,256 Crore
- Earnings
- pharmaceuticals
Reviewed byKeshav SehgalBlacklitt Research
Glaxosmithkline Pharmaceuticals (NSE: GLAXO) reported consolidated total income of ₹1,256 crore and net profit of ₹336 crore for the quarter ended 30 Sep 2026, it said in a filing on 03 Nov 2026. Standalone total income was ₹1,253 crore and net profit ₹335 crore.
Key highlights
Consolidated
Including its subsidiaries
- Total income: ₹1,256 crore, up 24.0% YoY and 27.9% QoQ
- Net profit and EPS: ₹336 crore, up 30.4% YoY; basic EPS ₹19.83
- Other income: ₹73 crore, including ₹42.09 crore interest on income tax refund
- Finance costs: ₹0.49 crore against ₹0.51 crore a year before
Standalone
The company on its own, without its subsidiaries
- Total income: ₹1,253 crore, up 24.7% YoY and 27.0% QoQ
- Net profit and EPS: ₹335 crore, up 31.2% YoY; basic EPS ₹19.76
- Other income: ₹73 crore, including ₹18 crore dividend from Biddle Sawyer Limited in six months
Summary
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 1,256 | 1,014 | +24.0% | 982 | +27.9% | |
| Revenue from operations | 1,184 | 980 | +20.8% | 938 | +26.1% |
| Other income | 73 | 34 | +116.8% | 44 | +66.3% |
| 336 | 257 | +30.4% | 237 | +41.6% | |
| Profit before tax | 459 | 354 | +29.8% | 322 | +42.5% |
| Finance costs | 0 | 1 | -3.9% | 1 | -49.5% |
| Depreciation | 15 | 17 | -13.8% | 16 | -5.2% |
| Tax expense | 123 | 97 | +27.9% | 85 | +44.8% |
| Net profit margin | 26.73% | 25.41% | +1.33 pp | 24.15% | +2.59 pp |
| EPS, basic (₹) | 19.83 | 15.20 | +30.5% | 14.00 | +41.6% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Other income rose 116.8% to ₹73 crore, while revenue from operations rose 20.8% to ₹1,184 crore. Other income is 5.8% of total income this quarter.
The notes say other income includes interest on an income tax refund of ₹42.09 crore. Consolidated profit before tax of ₹459.34 crore is 29.8% above the year-earlier level, and tax expense of ₹123.46 crore is 26.9% of profit before tax. Finance costs were ₹0.49 crore, against ₹0.51 crore a year earlier, so borrowing costs are small relative to income.
The consolidated exceptional items in the year ended 31 Mar 2026 included ₹17.98 crore (₹17.98 crore) on the sale of a non-operational land site, a figure outside this quarter.
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 1,253 | 1,005 | +24.7% | 986 | +27.0% | |
| Revenue from operations | 1,180 | 974 | +21.2% | 924 | +27.6% |
| Other income | 73 | 31 | +132.7% | 62 | +18.1% |
| 335 | 255 | +31.2% | 253 | +32.1% | |
| Profit before tax | 458 | 351 | +30.5% | 338 | +35.4% |
| Finance costs | 0 | 1 | -3.9% | 1 | -49.5% |
| Depreciation | 15 | 17 | -13.8% | 16 | -5.2% |
| Tax expense | 123 | 96 | +28.6% | 85 | +45.3% |
| Net profit margin | 26.71% | 25.38% | +1.34 pp | 25.69% | +1.02 pp |
| EPS, basic (₹) | 19.76 | 15.06 | +31.2% | 14.95 | +32.2% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Standalone results follow the same pattern. Net profit rose 31.2% YoY against total income growth of 24.7%, and other income of ₹73 crore is 5.8% of total income.
Standalone other income for the six months includes ₹18.00 crore (₹18 crore) of dividend from the wholly owned subsidiary Biddle Sawyer Limited. Standalone profit is ₹1.00 crore lower than consolidated, and consolidated net profit grew 30.4% YoY, slightly slower than standalone's 31.2%.
The company has one reportable segment, Pharmaceuticals, and the filing discloses no separate segment information.
Inference
The filing says the Board appointed Walker Chandiok & Co LLP as statutory auditors for a first term of five years from financial year 2027-28, subject to member approval at the forthcoming AGM. It also records a six-month dividend paid to shareholders of ₹969.93 crore, although the filing does not say which financial year that dividend relates to.
The filing does not say why other income moved as it did beyond the tax refund interest and the subsidiary dividend, nor why the auditor change is proposed.
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
